290 results
Page 3 of 15
6-K
jcppln vtms
1 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
3a4jsc lt
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
s7j5jeei9f591o
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
8zn2wzjont17
30 May 23
Current report (foreign)
6:11am
6-K
tn5fg3xs5ghk
17 May 23
Current report (foreign)
6:02am
6-K
5u26ub
11 May 23
Current report (foreign)
6:10am
6-K
lqnzfwlb6 6nkpb7
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
5jrjufu6nbjhwyqcjd
11 May 23
Current report (foreign)
6:07am
6-K
5x996bdtjbdzbah i4
30 Mar 23
Current report (foreign)
6:19am
6-K
ntboon9r
21 Dec 22
Current report (foreign)
6:01am
6-K
9ift l5hkpz41k9pq
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
29q4zma0qyf9
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
ruc2ccnezl94qklq1
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
r69mmhn6sbjbeixvn0aq
30 Nov 22
Current report (foreign)
6:28am
6-K
9zdl8olh
4 Nov 22
Current report (foreign)
6:01am
6-K
EX-99.1
jlvwmemunp59vq1fh452
27 Oct 22
Current report (foreign)
6:01am
6-K
1wu6tj52o1vt
14 Oct 22
Current report (foreign)
7:36am
6-K
80g ubje2qx
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
vnhyjnq1
23 Aug 22
Current report (foreign)
6:13am
6-K
EX-99.1
jedjwoo7dpy 60
4 Aug 22
Current report (foreign)
6:07am